Geron

Geron Sells Embryonic Stem Cell Business

Thumbnail image for Geron Sells Embryonic Stem Cell Business

I was right. Again. Last month, I predicted that Geron would sell its defunct embryonic stem cell business this year, and the one major ESCR human trial would be on the road to resuming. (Yes, I know there are a few other tiny studies ongoing.) One month later, and it has happened. From the Nature […]

Read the full article →

LA Times Circles the Wagons on ESCR

By Wesley J. Smith, J.D., Special Consultant to the CBC Consider this an addendum to my Weekly Standard piece on media bias in reporting the collapse of Geron’s embryonic stem cell project that came out on Saturday. The LA Times finally got around to reporting the Geron collapse. Apparently, it had to figure out how […]

Read the full article →

The Only Stem Cell News Biased Media Sees Fit to Print

By Wesley J. Smith, J.D., Special Consultant to the CBC Remember Ron Reagan’s nonsense speech about embryonic stem cell research (actually human cloning research) at the 2004 Democratic Convention? Media swooned at the garbage and the hype (e.g., Parkinson’s cures around 2014, “self repair kits” stored in hospitals). (Here’s my deconstruction in NRO.) Come to […]

Read the full article →

Are Human ESC Trials Premature?

By Wesley J. Smith, J.D., Special Consultant to the CBC Some in the ESCR community–and I am referring to those without moral objections–are worried that the coming ESC human trials are premature. From the story: Scientists are poised to inject cells created from embryonic stem cells into some patients with a progressive form of blindness […]

Read the full article →

Geron On Again, Off Again ESCR Human Trial, On Again: What if Doctors Oppose?

By Wesley J. Smith, J.D., Special Consultant to the CBC For years, Geron promised that human trials for its ESCR derived product to treat people with new spinal cord injuries would begin–next year. Then approval was obtained from the FDA. Then it was off. Now, it is back on again. From the story: Geron Corp. […]

Read the full article →

Geron Politicized Its Stem Cell Human Trial Request

By Wesley J. Smith, J.D., Special Consultant to the CBC So much for caring exclusively about alleviating the suffering of ill and disabled people. Geron’s head has admitted playing politics with the timing of its request to conduct the world’s first human embryonic stem cell trials on its ESC-based product to be tried on people […]

Read the full article →

Tumors Found in Boy With Fetal Tissue Stem Cell Treatment

I wrote a piece a few weeks ago about Geron Corporation being granted the first human clinical trials using embryonic stem cells in spinal cord injured patients: A seismic shift has occurred this week. For the first time ever in history, human embryonic stem cells will be injected into human subjects. Geron Corporation has enthusiastically […]

Read the full article →

Geron aims to be first in human trials with ESCs – Gains FDA Approval

Well I am way behind in blogging on this story. Mainly because it broke when I was in Washington DC last week. But this was certainly news coming down the pipeline as Geron has been making noise for years that they would be first to begin human embryonic stem cell clinical trials. Here are some […]

Read the full article →

FDA Delays Clinical Trails of Embryonic Stem Cells

Hah! The FDA, in its great and infinite wisdom said “now wait a minute” to Geron Corporation. Here’s the scoop in its entirety. The Geron Corporation announced Wednesday that its plans to begin the first clinical trial using embryonic stem cells had been delayed by federal regulators. The company, based in Menlo Park, Calif., had […]

Read the full article →

Geron aims to be first in human trials with ESCs

This is such bad news, I will post the whole announcement here: In a first, Geron made headlines at the BIO CEO conference in New York with its announcement that it could begin its first human trials using embryonic stem cells to treat spinal cord injuries as early as this spring. Geron first has to […]

Read the full article →